105 related articles for article (PubMed ID: 33851424)
1. The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study.
Almurjan A; Macfarlane H; Badhan RKS
Biopharm Drug Dispos; 2021 Jun; 42(6):252-262. PubMed ID: 33851424
[TBL] [Abstract][Full Text] [Related]
2. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
Almurjan A; Macfarlane H; Badhan RKS
J Pharm Pharmacol; 2020 Aug; 72(8):1049-1060. PubMed ID: 32346890
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
4. Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study.
Badhan RKS; Gittins R
J Subst Abuse Treat; 2021 Nov; 130():108521. PubMed ID: 34118695
[TBL] [Abstract][Full Text] [Related]
5. Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach.
Alenezi M; Badhan RKS
J Pharm Pharmacol; 2024 Jan; 76(2):122-137. PubMed ID: 38142123
[TBL] [Abstract][Full Text] [Related]
6. Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low.
Heinonen E; Blennow M; Blomdahl-Wetterholm M; Hovstadius M; Nasiell J; Pohanka A; Gustafsson LL; Wide K
Eur J Clin Pharmacol; 2021 Sep; 77(9):1323-1331. PubMed ID: 33751155
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.
Poweleit EA; Taylor ZL; Mizuno T; Vaughn SE; Desta Z; Strawn JR; Ramsey LB
Clin Pharmacokinet; 2023 Nov; 62(11):1621-1637. PubMed ID: 37755681
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
10. Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study.
Burhanuddin K; Badhan R
Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557319
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
[TBL] [Abstract][Full Text] [Related]
12. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
14. Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study.
Christensen J; Sandgaard AP; Sidenius P; Linnet K; Licht RW
Pharmacopsychiatry; 2012 May; 45(3):119-21. PubMed ID: 22426846
[TBL] [Abstract][Full Text] [Related]
15. Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy.
George B; Lumen A; Nguyen C; Wesley B; Wang J; Beitz J; Crentsil V
NPJ Syst Biol Appl; 2020 Nov; 6(1):36. PubMed ID: 33159093
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.
Yuce-Artun N; Baskak B; Ozel-Kizil ET; Ozdemir H; Uckun Z; Devrimci-Ozguven H; Suzen HS
Int J Clin Pharm; 2016 Apr; 38(2):388-94. PubMed ID: 26830411
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
Brandl EJ; Tiwari AK; Zhou X; Deluce J; Kennedy JL; Müller DJ; Richter MA
Pharmacogenomics J; 2014 Apr; 14(2):176-81. PubMed ID: 23545896
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
